A computerized version of the Short Form of the Face-Name Associative Memory Exam (FACEmemory®) for the early detection of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: Computerized neuropsychological tests for early detection of Alzheimer’s disease (AD) have attracted increasing interest. Memory for faces and proper names is a complex task because its association is arbitrary. It implicates associative occipito-temporal cerebral regions, which are disrupted in AD. The short form of the Face-Name Associative Memory Exam (FNAME-12), developed to detect preclinical and prodromal AD, asks individuals to learn the names and occupations associated with 12 faces. The current work advances this field by using voice recognition and touchscreen response format. The purpose of this study is to create the first self-administered episodic memory test, FACEmemory®, by adapting the FNAME-12 for tablet use with voice recognition, touchscreen answers, and automatic scoring. The test was minimally supervised by a psychologist to avoid technological problems during execution and scored manually to assess the reliability of the automatic scoring. The aims of the present study were (1) to determine whether FACEmemory® is a sensitive tool for the detection of cognitive impairment, (2) to examine whether performances on FACEmemory® are correlated with those on the S-FNAME (paper-and-pencil version with 16 images), and (3) to determine whether performances on FACEmemory® are related to AD biomarkers in the cerebrospinal fluid (CSF) (Aβ42, p-tau, and Aβ42/p-tau ratio). Methods: FACEmemory® was completed by 154 cognitively healthy (CH) individuals and 122 subjects with mild cognitive impairment, of whom 61 were non-amnestic (naMCI) and 61 amnestic (aMCI). A subsample of 65 individuals completed the S-FNAME, and 65 subjects received lumbar punctures. Results: Performance on FACEmemory® was progressively worse from CH to the naMCI and aMCI groups. A cutoff of 31.5 in total FACEmemory® obtained 80.5% and 80.3% sensitivity and specificity values, respectively, for discriminating between CH and aMCI. Automatically corrected FACEmemory® scores were highly correlated with the manually corrected ones. FACEmemory® scores and AD CSF biomarker levels were significantly correlated as well, mainly in the aMCI group. Conclusions: FACEmemory® may be a promising memory prescreening tool for detecting subtle memory deficits related to AD. Our findings suggest FACEmemory® performance provides a useful gradation of impairment from normal aging to aMCI, and it is related to CSF AD biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Buckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., Sheline, Y. I., Klunk, W. E., Mathis, C. A., Morris, J. C., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2177-05.2005 · Cited by 2,140
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
Mild Cognitive Impairment as a Clinical Entity and Treatment Target
Petersen, R. C., & Morris, J. C. (2005) · Archives of Neurology · doi:10.1001/archneur.62.7.1160 · Cited by 935
SAHAKIAN, B. J., MORRIS, R. G., EVENDEN, J. L., HEALD, A., LEVY, R., PHILPOT, M., & ROBBINS, T. W. (1988) · Brain · doi:10.1093/brain/111.3.695 · Cited by 666
Subjective cognitive complaints and amyloid burden in cognitively normal older individuals
Amariglio, R. E., Becker, J. A., Carmasin, J., Wadsworth, L. P., Lorius, N., Sullivan, C., Maye, J. E., Gidicsin, C., Pepin, L. C., Sperling, R. A., et al. (2012) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2012.08.011 · Cited by 472
Self-citationStatus of computerized cognitive testing in aging: a systematic review
Wild, K., Howieson, D., Webbe, F., Seelye, A., & Kaye, J. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2008.07.003 · Cited by 436
Vanderstichele, H., Bibl, M., Engelborghs, S., Le Bastard, N., Lewczuk, P., Molinuevo, J. L., Parnetti, L., Perret‐Liaudet, A., Shaw, L. M., Teunissen, C., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.07.004 · Cited by 358
Cited by
Gender Difference in the Prevalence of Insomnia: A Meta-Analysis of Observational Studies
Zeng, L.-N., Zong, Q.-Q., Yang, Y., Zhang, L., Xiang, Y.-F., Ng, C. H., Chen, L.-G., & Xiang, Y.-T. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.577429 · Cited by 360
Cano, A., Turowski, P., Ettcheto, M., Duskey, J. T., Tosi, G., Sánchez-López, E., García, M. L., Camins, A., Souto, E. B., Ruiz, A., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00864-x · Cited by 122
“AD is now recognized as a continuum of neurological decline that can be identified and staged through a combination of neuropathological findings and in vivo biomarkers [17, 18].”
BackgroundSelf-citationBenussi, A., Ashton, N. J., Karikari, T. K., Gazzina, S., Premi, E., Benussi, L., Ghidoni, R., Rodriguez, J. L., Emeršič, A., Binetti, G., et al. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-200608 · Cited by 113
Wu, X., Ji, G.-J., Geng, Z., Wang, L., Yan, Y., Wu, Y., Xiao, G., Gao, L., Wei, Q., Zhou, S., et al. (2022) · Brain Stimulation · doi:10.1016/j.brs.2021.11.007 · Cited by 109
“Measures of AM, which 60 are most vulnerable to AD’s pathological processes, are correlated with cerebrospinal fluid markers of 61 AD neurodegeneration [8].”
BackgroundAlzheimer's disease digital biomarkers multidimensional landscape and AI model scoping review
Qi, W., Zhu, X., Wang, B., Shi, Y., Dong, C., Shen, S., Li, J., Zhang, K., He, Y., Zhao, M., et al. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01640-z · Cited by 78
Metadata
- Authors
- Alegret, M., Muñoz, N., Roberto, N., Rentz, D. M., Valero, S., Gil, S., Marquié, M., Hernández, I., Riveros, C., Sanabria, A., Perez-Cordon, A., Espinosa, A., Ortega, G., Mauleón, A., Abdelnour, C., Rosende-Roca, M., Papp, K. V., Orellana, A., Benaque, A., Tarraga, L., Ruiz, A., & Boada, M.
- Venue
- Alzheimer's Research & Therapy
- Published
- 2020-03-16
- Volume
- 12
- Issue
- 1
- Pages
- 25-25
- ISSN
- 1758-9193 (ISSN-L)
- OpenAlex
- W3011067510
- Cited by
- 55
- References
- 9
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A computerized version of the Short Form of the Face-Name Associative Memory Exam (FACEmemory®) for the early detection of Alzheimer’s disease. https://app.cochat.ai/papers/10.1186/s13195-020-00594-6
- The paper
- Alegret, M., Muñoz, N., Roberto, N., Rentz, D. M., Valero, S., Gil, S., Marquié, M., Hernández, I., Riveros, C., Sanabria, A., Perez-Cordon, A., Espinosa, A., Ortega, G., Mauleón, A., Abdelnour, C., Rosende-Roca, M., Papp, K. V., Orellana, A., Benaque, A., . . . Boada, M. (2020). A computerized version of the Short Form of the Face-Name Associative Memory Exam (FACEmemory®) for the early detection of Alzheimer’s disease. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-020-00594-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.